PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Poly ICLC

Drugs in development · updated 30 October 2026

Poly ICLC: clinical trials and development status

Other names and codes: Hiltonol

NLM verified identityNot approved in the USNo EMA authorisation

As of 30 October 2026 Poly ICLC is in 22 active clinical trials (recruiting or ongoing, phases I–III) for 26 diseases. The most advanced phase is II.

22Active trials
IIMost advanced phase
26Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Poly ICLC and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Non-small-cell lung carcinomaI–II3NCT01720836
Triple-negative breast neoplasmII3NCT03606967
Prostatic NeoplasmsII2NCT06343077
MelanomaI4NCT06529822
GlioblastomaI3NCT03223103
Breast neoplasmI2NCT04616248
Basal-cell carcinoma of the skinI1NCT04616248
Biliary tract neoplasmI1NCT06564623
Bladder neoplasmI1NCT06529822
Bone neoplasmI1NCT04616248
Brain NeoplasmsI1NCT03223103
CarcinomaI1NCT06564623
Colonic neoplasmI1NCT06411691
Colorectal neoplasmI1NCT06411691
GliomaI1NCT05283109
Intraductal carcinoma of the breastI1NCT06218303
Lung neoplasmI1NCT05098210
Merkel cell carcinomaI1NCT04616248
MetastasisI1NCT05098210
MyelofibrosisI1NCT05025488
NeoplasmI1NCT03223103
OsteosarcomaI1NCT04616248
Pancreatic neoplasmI1NCT06411691
SarcomaI1NCT04616248
Smoldering Multiple MyelomaI1NCT02886065
Thrombocythemia, EssentialI1NCT05025488

Everything on Poly ICLC

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch